
The FDA has approved Roches Wilserdly, taken with everolimus, for certain adults with advanced breast cancer that has returned or progressed after hormone treatment.
In patients with an ESR1 mutation, the combination reduced the risk of disease progression or death by 62% compared with standard hormone therapy plus everolimus.
The treatment is entirely oral, offering an option that does not require injections, although patients still need monitoring for side effects.
The Food and Drug Administration (FDA) has approved Roches breast cancer drug Wilserdly, providing a new treatment option for patients whose disease has become harder to control with hormone therapy.
The approval covers the drug, also known as giredestrant, in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, locally advanced, or metastatic breast cancer with an ESR1 mutation. Eligible patients must have experienced recurrence during or after hormone-based treatment following initial therapy, or progression after hormone treatment for metastatic disease.
Author: Mark Huffman
Source: Consumer Affairs
Posted: 2026-11-18 13:51:44









